ArticleCase reports in pediatrics2025
Inspissated Bile Syndrome and Crigler-Najjar Syndrome Type II: When Two Rare Conditions Converge.
Article in Case reports in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inspissated bile syndrome (IBS) is a rare neonatal condition characterized by thickened bile leading to cholestasis, while Crigler-Najjar syndrome type II (CNS-II) is an autosomal recessive disorder resulting in unconjugated hyperbilirubinemia. Both conditions pose significant risks, particularly when they converge during pregnancy. Case Presentation: We report a unique case involving a 20 day-old female neonate born to a mother with CNS-II who discontinued phenobarbital treatment during pregnancy. The mother presented with elevated indirect bilirubin levels (total 32, and direct 0.4 mg/dL) and normal liver function test, while the neonate exhibited prolonged jaundice and cholestasis with direct hyperbilirubinemia (total 8, and direct 5.4 mg/dL) upon admission. Treatment included ursodeoxycholic acid for the neonate, leading to normalization of bilirubin levels. The neonate's growth and neurological development remained normal at 6 months. Discussion: This case emphasizes the significant risks associated with untreated CNS-II during pregnancy, which likely contributed to the neonate's IBS. Existing literature highlights the importance of maternal management in preventing severe neonatal complications associated with hyperbilirubinemia. Conclusion: This case highlights the importance of timely intervention in managing maternal metabolic disorders during pregnancy to improve neonatal health. Further research is essential to develop optimal treatment strategies for such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.